0.10Open0.10Pre Close0 Volume5 Open Interest5.00Strike Price0.00Turnover404.78%IV174.19%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.1784Delta0.1849Gamma18.60Leverage Ratio-0.0142Theta0.0001Rho3.32Eff Leverage0.0009Vega
Standard BioTools Stock Discussion
assay services, kits and related revenue in 2024; and
-- Ended the quarter with cash, cash equivalents, restricted cash and
short-term investments of $464 million, after accounting for $71 million
cash payments for merger-related expenses, settlement of year-end
operating accruals, debt retirement and completed stock buybacks.
2 MINUTES AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
Benzinga· 1 min ago
No comment yet